RE-IGNITE: Understanding Metabolism, Energy Balance & Peptide Research
RE-IGNITE is an educational resource about metabolism, energy balance, body composition, and current research involving AOD-9604 and MOTS-c.
Metabolism includes the biological processes the body uses to convert nutrients into energy, maintain tissues, regulate energy storage, and support normal physiological functions.
Researchers have investigated peptides that may influence metabolic pathways, fat metabolism, mitochondrial function, and energy regulation. Much of this research remains experimental, and findings from laboratory or animal studies should not be interpreted as established clinical benefits in humans.
Understanding Energy Balance and Metabolism
Body weight and body composition are influenced by a complex interaction of biological, behavioral, and environmental factors. These can include:
Fat storage and lipolysis:
Stored fat primarily consists of triglycerides. When energy is required, triglycerides can be broken down through a process called lipolysis, releasing fatty acids and glycerol that can participate in energy metabolism. Fat metabolism is tightly regulated and cannot be attributed to a single hormone, peptide, or metabolic pathway.
AOD-9604
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone. It was developed and investigated for potential effects related to fat metabolism and obesity without attempting to reproduce all of the physiological actions of full-length growth hormone.
Preclinical research has examined AOD-9604 in relation to lipid metabolism and body weight. Human studies have also evaluated orally administered AOD-9604 in people with obesity. However, the available evidence has not established AOD-9604 as an FDA-approved treatment for obesity or weight loss.
In 2024, FDA reviewed AOD-9604–related bulk drug substances and concluded that available clinical safety information was limited and there was insufficient information to support long-term patient safety. FDA also reported that it did not identify human information for the proposed subcutaneous or transdermal routes of administration. U.S. Food and Drug Administration
MOTS-c
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a mitochondrial-derived peptide that has been investigated for its potential involvement in cellular metabolism, mitochondrial signaling, metabolic adaptation, and responses to exercise.
Human physiology studies have examined naturally occurring MOTS-c and observed changes in circulating levels associated with physiological conditions such as exercise. PubMed
Much of the research investigating externally administered MOTS-c and metabolic effects has involved laboratory and animal models. Research into mitochondrial-derived peptides is continuing, but evidence establishing exogenous MOTS-c as a safe and effective treatment for obesity or fat loss in humans is lacking. MOTS-c is not an FDA-approved medication for weight loss or metabolic disease.
Understanding Fat Metabolism
Fat metabolism involves numerous interacting biological systems. Hormones, enzymes, the nervous system, skeletal muscle, liver, adipose tissue, gastrointestinal signaling, and mitochondria all participate in regulating how energy is stored and used.
Research involving AOD-9604 and MOTS-c has explored different parts of these biological systems.
However, identifying a biological mechanism does not establish that administering a substance will produce clinically meaningful fat loss in humans.
This distinction is particularly important when evaluating early-stage peptide research.
Understanding the Evidence
Evidence involving AOD-9604 and MOTS-c varies considerably. Research includes:
Preclinical findings can help researchers identify potential biological mechanisms and determine whether additional investigation is warranted. They do not establish clinical effectiveness.
High-quality controlled human clinical trials are necessary to determine whether an investigational substance is effective, what dose may be appropriate, which patients may benefit, and what short- and long-term risks may occur. Neither AOD-9604 nor MOTS-c is an FDA-approved treatment for obesity or fat loss.
Metabolic Health
Metabolic health extends beyond body weight alone. Healthcare professionals may consider factors including:
Evidence-based approaches to weight and metabolic management depend on the individual's health status and may include nutrition, physical activity, behavioral interventions, treatment of underlying conditions, and FDA-approved medications when clinically appropriate.
Regulatory and Safety Considerations
AOD-9604 and MOTS-c are not FDA-approved medications for obesity, fat loss, or metabolic optimization.
FDA's review of AOD-9604 identified limitations in the available safety evidence and concluded that use of AOD-9604–related bulk drug substances in compounding may raise safety concerns. U.S. Food and Drug Administration
Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. U.S. Food and Drug Administration
Research findings involving experimental peptides should therefore be distinguished from evidence supporting FDA-approved medications.
Questions to Discuss With a Healthcare Professional
Patients learning about metabolism, weight management, and peptide research may wish to ask:
Continuing Research
Research into metabolism, mitochondrial biology, obesity, energy regulation, and peptide signaling continues to evolve. AOD-9604 and MOTS-c have been investigated in different experimental settings, but the amount and quality of human clinical evidence differ substantially.
Additional controlled human research is needed to determine whether experimental findings involving these peptides translate into safe and effective medical treatments. Patients should distinguish between biological mechanisms, preclinical research, human clinical evidence, and FDA-approved treatments when evaluating peptide information.
Educational Resources & Citations
This page is provided for general educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment.
References to peptides, metabolic pathways, biological mechanisms, laboratory research, animal studies, or areas of clinical investigation are provided for educational purposes and should not be interpreted as a recommendation or endorsement of a particular substance or treatment.
Discussion of an investigational substance does not establish that the substance is safe, effective, FDA-approved, or appropriate for medical use.
Treatment decisions should be individualized and made with an appropriately licensed healthcare professional based on medical history, diagnosis, current health, medications, potential risks, available clinical evidence, and professional medical judgment.
FDA approval status, compounding policies, clinical evidence, and regulatory requirements may change. Current information should be verified through the U.S. Food & Drug Administration and other recognized medical resources.